A tumor immunotherapy composition based on specific immune cells, preparation method and application

CN122278773APending Publication Date: 2026-06-26SUZHOU ROYALTECH MED CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2020-09-04
Publication Date
2026-06-26

Smart Images

  • Figure CN122278773A_ABST
    Figure CN122278773A_ABST
Patent Text Reader

Abstract

This disclosure relates to a tumor immunotherapy composition, preparation method, and application based on specific immune cells, particularly specific immune cells activated by attenuated Listeria monocytogenes carrying non-integrating antigenic peptide plasmids. The disclosure involves extracting T cells in vitro, co-culturing T cells with antigen-presenting cells activated by attenuated Listeria monocytogenes, and generating T cells with specific tumor antigenic peptides in vitro. These specific T cells are then reinfused into the body to generate a tumor-specific immune response. The technical solution of this disclosure can specifically activate tumor-specific T cells, thereby triggering a series of anti-tumor immune responses. Furthermore, the process does not require genetic modification of autologous cells, significantly improving both targeting and safety.
Need to check novelty before this filing date? Find Prior Art